Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study
Abstract Background Ovarian toxicity is a dreaded complication of cyclophosphamide (CYC). With the use of lower cumulative doses of intravenous CYC (modified NIH regimens) and availability of better markers of ovarian toxicity, the incidence of ovarian dysfunction needs reassessment. Lupus disease a...
Main Authors: | Shefali Khanna Sharma, Siddharth Jain, Pooja Bahl, Pragna Potturi, Manish Rathi, Shankar Naidu, Naresh Sachdeva, Varun Dhir, Sanjay Jain |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-020-02292-y |
Similar Items
-
Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
by: Arun Sedhain, et al.
Published: (2018-07-01) -
Retrospective comparison of cyclophosphamide and mycophenolate mofetil in lupus nephritis at Groote Schuur Hospital nephrology unit
by: Sogayise, Phelisa
Published: (2021) -
Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study
by: Xuan Luo, et al.
Published: (2020-07-01) -
The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
by: Anji Xiong, et al.
Published: (2021-03-01) -
Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis
by: Seung Woon Park, et al.
Published: (2016-06-01)